Drug Discovery World

NOVEMBER 3, 2023

New UK therapy option for hard-to-treat lymphoma The MHRA has granted conditional marketing authorisation for Abbvie’s Tepkinly (epcoritamab) as a bispecific treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.

Clinical Trials 130

Clinical Trials Drugs Trials Therapies 130

Drug Discovery World

MAY 21, 2024

Modern experimental procedures, such as immunisation, B-cell screening, and synthetic library generation, have been pivotal in developing approximately 80 FDA-approved antibody therapeutics. These targets, along with many others, are universally deemed as ‘difficult-to-drug’ targets.

FDA Approval 147

FDA Approval Disease FDA Treatment 147

Alta Sciences

JULY 31, 2024

Food and Drug Administration (FDA) published a draft guidance to ensure greater diversity in clinical trials, which is expected to become a final guidance by June 2025. Why Diversity in Clinical Trials Matters A wide variety of factors, from age or biological sex to environmental conditions and lifestyle choices (e.g.,

Clinical Trials 52

Clinical Trials Trials Clinical Pharmacology Pharmacokinetics 52